Modelo predictivo multiparamétrico del estatus axilar en pacientes con cáncer de mama: carga tumoral total y perfil molecular. Estudio multicéntrico

Bernet, Laia; García‐Gómez, Juan Miguel; Muñoz, Rafael Cano; Piñero, Antonio; Ramírez, Alfonso; Rodrigo, María Luisa Jiménez; Heras, Juan M. de la Cámara de las; Burgués, O; Ruiz, Irene Fuensanta Muñoz; Tormos, Bárbara

doi:10.1016/j.senol.2015.04.001

Cited by 3 publications

(1 citation statement)

References 33 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We were unable to identify previous studies that assessed a possible interaction of the TTL and the MS-PAM50 or MS-IHC on the prediction of non-SLN involvement. Bernet et al 22 analyzed 373 patients with infiltrating carcinoma of the breast and metastatic SLN submitted to ALND to assess the capacity of both the TTL and the MS-IHC to predict non-SLN involvement, and did not find a statistically significant effect of the MS-IHC in their univariate analysis ( P = .10). However, they observed a slight improvement of the AUC ROC (from 0.71 to 0.74) when the MS-IHC was added to a logistic regression model based on TTL, histological type and grade, tumor size, and ILV.…”

Section: Discussionmentioning

confidence: 99%

OSNA Total Tumor Load for the Prediction of Axillary Involvement in Breast Cancer Patients: Should We use Different Thresholds According to the Intrinsic Molecular Subtype? MOTTO Study

Bernet

Hardisson

Rodrigo

et al. 2023

Clin Med�Insights�Pathol

View full text Add to dashboard Cite

Aims: To assess the impact of the molecular subtype (MS) on the total number of CK19 mRNA copies in all positive SLN (TTL) threshold, to predict non-SLN affectation, and to compare 5 years progression-free survival (PFS) according to the risk of recurrence (ROR) group by PAM50. Methods: Cohort with infiltrating breast cancer with intra-operative metastatic SLN detected by one-step nucleic acid amplification (OSNA) assay who underwent subsequent ALND. Logistic regression was used to assess a possible interaction between TTL and MS(Triple Negative, Her-2-Enriched, Luminal A, or Luminal B), or hormone receptors (HR: positive or negative) by immunohistochemistry (IMH). Cox regression was used to compare PFS and OS in the 3 ROR groups (high, medium, or low). Results: TTL was predictive of non-SLN affectation in both univariate (OR [95% CI]: 1.72 [1.43, 2.05], P < .001) and multivariate (1.55 [95% CI: 1.04, 2.32], P = .030) models, but MS-IMH or HR-IMH, and their interactions with TTL were not (best multivariate model: HR + main effect OR 1.16 [95% CI: 0.18, 7.64], P = .874; interaction OR: 1.04 [0.7, 1.55], P = .835; univariate model: HR + main effect OR: 1.44 [95% CI: 0.85, 2.44], P = .180). PFS was lower in the high-risk ROR group (81.1%) than in the low-risk group (93.9%) (HR: 3.68 [95 CI: 1.70, 7.94], P < .001). Conclusions: our results do not provide evidence to support the utilization of subtype-specific thresholds for TTL values to make therapeutic decisions on the axilla. The ROR group was predictive of 5 years-PFS.

show abstract

Section: Discussionmentioning

confidence: 99%